Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Report Overview
2023
Base Year
2018-2023
Historical Year
2024-2032
Forecast Year
Leading Companies in the North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market
The key features of the market report include funding and investment analysis, and partnerships and collaborations analysis by the leading key players. The major companies in the market are as follows:
CSL Behring
This United States-based biopharmaceutical company, specializing in manufacturing plasma-derived and recombination therapeutic products, is known for its liquid IgG product Hizentra indicated for the treatment of chronic inflammatory demyelinating polyneuropathy.
Grifols, S.A.
Grifols, S.A., a multinational pharmaceutical and chemical manufacturer, is a leading provider of blood plasma-based products. The company sells its intravenous immunoglobulin (IVIG) under the brands Flebogamma® and Gamunex® for chronic inflammatory demyelinating polyneuropathy (CIDP) patients in the United States and Canada.
Shire
Shire plc, a UK-founded Jersey-registered specialty biopharmaceutical company, is focused on developing treatments for rare diseases. In 2019, it was acquired by Takeda Pharmaceuticals.
Octapharma AG
This Switzerland-based pharmaceutical company is one of the largest providers of high-quality human proteins from human plasma and human cell lines. It has a robust immunoglobulin product portfolio for patients requiring IgG immunotherapy.
Other players in the market include Biogen Idec, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Sanofi, and Roche Holding AG.
North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Report Snapshots
North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Size
North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Analysis
North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Key Questions Answered in the Report
The North America chronic inflammatory demyelinating polyneuropathy therapeutics market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 6.60% during the forecast period of 2024-2032.
The rising advancements in personalized medicine and heightened patient awareness are fuelling the demand for the market.
One of the significant trends in the market is the rise in approvals of novel therapeutics by health regulatory authorities. In January 2024, Takeda Pharmaceuticals received FDA approval for its subcutaneous immunoglobin (SCIG) infusion HYQVIA as maintenance therapy for adult chronic inflammatory demyelinating polyneuropathy patients.
Based on the drug type, the market is segmented into corticosteroids, and immunoglobulin, among others.
By route of administration, the market is divided into oral and injectable.
Major distribution channels of the market include hospital pharmacies, retail pharmacies, and online pharmacies.
The market segmentation by countries includes the United States and Canada.
The key players in the market are CSL Behring, Grifols, S.A., Shire, Octapharma AG, Biogen Idec, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Sanofi, and Roche Holding AG.
Purchase Full Report
Datasheet
- Selected Sections, One User
- Printing Not Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Single User License
One User
- All Sections, One User
- One Print Allowed
- Email Delivery in PDF
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
Five Users
- All Sections, Five Users
- Five Prints Allowed
- Email Delivery in PDF
- Free Limited Customisation
- Post Sales Analyst Support
50% Discount on Next Update
Corporate License
Unlimited Users
- All Sections, Unlimited Users
- Unlimited Prints Allowed
- Email Delivery in PDF + Excel
- Free Limited Customisation
- Post Sales Analyst Support
- 50% Discount on Next Update
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Subscribe to our Newsletter
By subscribing you agree to with our privacy policy and provide
consent to
receive
updates
from our company.
Our Offices
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124